A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort

被引:125
作者
Marzouka, Nour-al-dain [1 ]
Eriksson, Pontus [1 ]
Rovira, Carlos [1 ]
Liedberg, Fredrik [2 ]
Sjodahl, Gottfrid [2 ]
Hoglund, Mattias [1 ]
机构
[1] Lund Univ, Div Oncol & Pathol, Dept Clin Sci, Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Div Urol Res, Dept Translat Med, Malmo, Sweden
来源
SCIENTIFIC REPORTS | 2018年 / 8卷
基金
瑞典研究理事会;
关键词
BLADDER-CANCER; MOLECULAR SUBTYPES; CLASSIFICATION; IDENTIFICATION; METHYLATION; BASAL;
D O I
10.1038/s41598-018-22126-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Global gene expression analysis has been a major tool for urothelial carcinoma subtype discovery. This approach has revealed extensive complexity both in intrinsic features of the tumor cells and in the microenvironment. However, global gene expression cannot distinguish between gene expression signals originating from the tumor cells proper and from normal cells in the biopsy. Here, we use a large cohort of advanced urothelial carcinomas for which both gene expression data and extensive immunohistochemistry are available to create a supervised mRNA expression centroid classifier. This classifier identifies the major Lund taxonomy tumor cell phenotypes as defined by IHC. We apply this classifier to the independent TCGA dataset and show excellent associations between identified subtypes and genomic features. We validate a progressed version of Urotheliallike A (UroAProg) that shows FGFR3 mutations and CDKN2A deletions, and we show that the variant Urotheliallike C is almost devoid of FGFR3 mutations. We show that Genomically Unstable tumors are very distinct from Urotheliallike tumors at the genomic level, and that tumors classified as Basal/SCClike all complied with the established definition for Basal/SCClike tumors. We identify the Mesenchymallike and Smallcell/ Neuroendocrinelike subtypes, and demonstrate that patients with UroB and Sc/NElike tumors show the worst overall survival.
引用
收藏
页数:12
相关论文
共 38 条
  • [31] Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer
    Siefker-Radtke, Arlene O.
    Kamat, Ashish M.
    Grossman, H. Barton
    Williams, Dallas L.
    Qiao, Wei
    Thall, Peter F.
    Dinney, Colin P.
    Millikan, Randall E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2592 - 2597
  • [32] Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification
    Sjodahl, Gottfrid
    Eriksson, Pontus
    Liedberg, Fredrik
    Hoglund, Mattias
    [J]. JOURNAL OF PATHOLOGY, 2017, 242 (01) : 113 - 125
  • [33] Toward a Molecular Pathologic Classification of Urothelial Carcinoma
    Sjodahl, Gottfrid
    Lovgren, Kristina
    Lauss, Martin
    Patschan, Oliver
    Gudjonsson, Sigurdur
    Chebil, Gunilla
    Aine, Mattias
    Eriksson, Pontus
    Mansson, Wiking
    Lindgren, David
    Ferno, Marten
    Liedberg, Fredrik
    Hoglund, Mattias
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2013, 183 (03) : 681 - 691
  • [34] A Molecular Taxonomy for Urothelial Carcinoma
    Sjodahl, Gottfrid
    Lauss, Martin
    Lovgren, Kristina
    Chebil, Gunilla
    Gudjonsson, Sigurdur
    Veerla, Srinivas
    Patschan, Oliver
    Aine, Mattias
    Ferno, Marten
    Ringner, Markus
    Mansson, Wiking
    Liedberg, Fredrik
    Lindgren, David
    Hoglund, Mattias
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3377 - 3386
  • [35] The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
    Vazquez, Ramiro
    Riveiro, Maria E.
    Astorgues-Xerri, Lucile
    Odore, Elodie
    Rezai, Keyvan
    Erba, Eugenio
    Panini, Nicolo
    Rinaldi, Andrea
    Kwee, Ivo
    Beltrame, Luca
    Bekradda, Mohamed
    Cvitkovic, Esteban
    Bertoni, Francesco
    Frapolli, Roberta
    D'Incalci, Maurizio
    [J]. ONCOTARGET, 2017, 8 (05) : 7598 - 7613
  • [36] Comprehensive molecular characterization of urothelial bladder carcinoma
    Weinstein, John N.
    Akbani, Rehan
    Broom, Bradley M.
    Wang, Wenyi
    Verhaak, Roeland G. W.
    McConkey, David
    Lerner, Seth
    Morgan, Margaret
    Creighton, Chad J.
    Smith, Carolyn
    Kwiatkowski, David J.
    Cherniack, Andrew D.
    Kim, Jaegil
    Pedamallu, Chandra Sekhar
    Noble, Michael S.
    Al-Ahmadie, Hikmat A.
    Reuter, Victor E.
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    Bochner, Bernard H.
    Solit, David B.
    Koppie, Theresa
    Robinson, Brian
    Gordenin, Dmitry A.
    Fargo, David
    Klimczak, Leszek J.
    Roberts, Steven A.
    Au, Jessie
    Laird, Peter W.
    Hinoue, Toshinori
    Schultz, Nikolaus
    Ramirez, Ricardo
    Hansel, Donna
    Hoadley, Katherine A.
    Kim, William Y.
    Damrauer, Jeffrey S.
    Baylin, Stephen B.
    Mungall, Andrew J.
    Robertson, A. Gordon
    Chu, Andy
    Kwiatkowski, David J.
    Sougnez, Carrie
    Cibulskis, Kristian
    Lichtenstein, Lee
    Sivachenko, Andrey
    Stewart, Chip
    Lawrence, Michael S.
    Getz, Gad
    Lander, Eric
    Gabriel, Stacey B.
    [J]. NATURE, 2014, 507 (7492) : 315 - 322
  • [37] Inferring tumour purity and stromal and immune cell admixture from expression data
    Yoshihara, Kosuke
    Shahmoradgoli, Maria
    Martinez, Emmanuel
    Vegesna, Rahulsimham
    Kim, Hoon
    Torres-Garcia, Wandaliz
    Trevino, Victor
    Shen, Hui
    Laird, Peter W.
    Levine, Douglas A.
    Carter, Scott L.
    Getz, Gad
    Stemke-Hale, Katherine
    Mills, Gordon B.
    Verhaak, Roel G. W.
    [J]. NATURE COMMUNICATIONS, 2013, 4
  • [38] Zhang J., 2017, BIOCONDUCTOR